Clinical Trial

Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To observe and evaluate the efficacy and safety of selective internal radiotherapy (SIRT) based on transarterial radioembolization with yttrium (90Y) microspheres combined with immune checkpoint inhibitors and anti-angiogenic-drug sequential hepatic arterial infusion chemotherapy (HAIC) for the treatment of initially unresectable hepatocellular carcinoma with transformation potential.
Trial Details
NCT Number NCT06867432
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-10